Millennium Pharmaceuticals has agreed to acquire Cambridge Discovery Chemistry, a wholly-owned subsidiary of the UK’s Oxford Molecular Group, for $53 million in cash.
To finance the deal, Millennium said it would sell securities in a private placement.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
